164 related articles for article (PubMed ID: 31605293)
21. Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
Crabb SJ; Danson S; Catto JWF; Hussain S; Chan D; Dunkley D; Downs N; Marwood E; Day L; Saunders G; Light M; Whitehead A; Ellis D; Sarwar N; Enting D; Birtle A; Johnson B; Huddart R; Griffiths G
Clin Cancer Res; 2021 Apr; 27(7):1882-1892. PubMed ID: 33472913
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma.
Jueliger S; Lyons J; Cannito S; Pata I; Pata P; Shkolnaya M; Lo Re O; Peyrou M; Villarroya F; Pazienza V; Rappa F; Cappello F; Azab M; Taverna P; Vinciguerra M
Epigenetics; 2016 Oct; 11(10):709-720. PubMed ID: 27646854
[TBL] [Abstract][Full Text] [Related]
23. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
[TBL] [Abstract][Full Text] [Related]
24. The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer.
Luker AJ; Graham LJ; Smith TM; Camarena C; Zellner MP; Gilmer JS; Damle SR; Conrad DH; Bear HD; Martin RK
BMC Immunol; 2020 Feb; 21(1):8. PubMed ID: 32106810
[TBL] [Abstract][Full Text] [Related]
25. Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method.
Liu Z; Marcucci G; Byrd JC; Grever M; Xiao J; Chan KK
Rapid Commun Mass Spectrom; 2006; 20(7):1117-26. PubMed ID: 16523529
[TBL] [Abstract][Full Text] [Related]
26. Elimination pathways of [14C]losoxantrone in four cancer patients.
Joshi AS; Pieniaszek HJ; Vokes EE; Vogelzang NJ; Davidson AF; Richards LE; Chai MF; Finizio M; Ratain MJ
Drug Metab Dispos; 2001 Feb; 29(2):96-9. PubMed ID: 11159796
[TBL] [Abstract][Full Text] [Related]
27. Mass balance, excretion and metabolism of [¹⁴C] ASA404 in cancer patients in a phase I trial.
McKeage MJ; Fong PC; Hong X; Flarakos J; Mangold J; Du Y; Tanaka C; Schran H
Cancer Chemother Pharmacol; 2012 May; 69(5):1145-54. PubMed ID: 22212299
[TBL] [Abstract][Full Text] [Related]
28. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
[TBL] [Abstract][Full Text] [Related]
29. Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of
van Andel L; Rosing H; Tibben MM; Lucas L; Lubomirov R; Avilés P; Francesch A; Fudio S; Gebretensae A; Hillebrand MJX; Schellens JHM; Beijnen JH
Cancer Chemother Pharmacol; 2018 Sep; 82(3):441-455. PubMed ID: 29974200
[TBL] [Abstract][Full Text] [Related]
30. A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma.
Ligon JA; Sundby RT; Wedekind MF; Arnaldez FI; Del Rivero J; Wiener L; Srinivasan R; Spencer M; Carbonell A; Lei H; Shern J; Steinberg SM; Figg WD; Peer CJ; Zimmerman S; Moraly J; Xu X; Fox S; Chan K; Barbato MI; Andresson T; Taylor N; Pacak K; Killian JK; Dombi E; Linehan WM; Miettinen M; Piekarz R; Helman LJ; Meltzer P; Widemann B; Glod J
Clin Cancer Res; 2023 Jan; 29(2):341-348. PubMed ID: 36302175
[TBL] [Abstract][Full Text] [Related]
31. An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.
van sen Bongard HJ; Pluim D; Rosing H; Nan-Offeringa L; Schot M; Ravic M; Schellens JH; Beijnen JH
Anticancer Drugs; 2002 Sep; 13(8):807-14. PubMed ID: 12394264
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors.
Nijenhuis CM; Hellriegel E; Beijnen JH; Hershock D; Huitema AD; Lucas L; Mergui-Roelvink M; Munteanu M; Rabinovich-Guilatt L; Robertson P; Rosing H; Spiegelstein O; Schellens JH
Invest New Drugs; 2016 Oct; 34(5):565-74. PubMed ID: 27221729
[TBL] [Abstract][Full Text] [Related]
35. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
Roboz GJ; Kantarjian HM; Yee KWL; Kropf PL; O'Connell CL; Griffiths EA; Stock W; Daver NG; Jabbour E; Ritchie EK; Walsh KJ; Rizzieri D; Lunin SD; Curio T; Chung W; Hao Y; Lowder JN; Azab M; Issa JJ
Cancer; 2018 Jan; 124(2):325-334. PubMed ID: 29211308
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Cashen AF; Shah AK; Todt L; Fisher N; DiPersio J
Cancer Chemother Pharmacol; 2008 Apr; 61(5):759-66. PubMed ID: 17564707
[TBL] [Abstract][Full Text] [Related]
37. Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study.
Jansen RS; Rosing H; Wijermans PW; Keizer RJ; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1457-66. PubMed ID: 22382880
[TBL] [Abstract][Full Text] [Related]
38. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients.
Clive S; Woo MM; Nydam T; Kelly L; Squier M; Kagan M
Cancer Chemother Pharmacol; 2012 Oct; 70(4):513-22. PubMed ID: 22864948
[TBL] [Abstract][Full Text] [Related]
39. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.
Fang F; Balch C; Schilder J; Breen T; Zhang S; Shen C; Li L; Kulesavage C; Snyder AJ; Nephew KP; Matei DE
Cancer; 2010 Sep; 116(17):4043-53. PubMed ID: 20564122
[TBL] [Abstract][Full Text] [Related]
40. Mass balance and pharmacokinetics of an oral dose of
Dai X; Karol MD; Hitron M; Hard ML; Blanchard JE; Eraut NCJE; Rich N; Gufford BT
Pharmacol Res Perspect; 2021 Feb; 9(1):e00722. PubMed ID: 33576192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
